Top 10 Companies in the Montelukast Sodium Market (2026): Market Leaders Powering Global Respiratory Care

MARKET INSIGHTS

The Global Montelukast Sodium Market was valued at USD 358 million in 2024 and is projected to grow from USD 413 million in 2025 to USD 882 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 14.1% during the forecast period. This growth is driven by increasing respiratory disease prevalence worldwide, with the WHO estimating 339 million asthma sufferers globally.

Montelukast Sodium Market – View in Detailed Research Report

Montelukast sodium is a leukotriene receptor antagonist used for prophylaxis and chronic treatment of respiratory conditions including asthma, allergic rhinitis, and exercise-induced bronchoconstriction. The hygroscopic white powder formulation demonstrates high solubility in ethanol, methanol, and water while being practically insoluble in acetonitrile.

Morepen Laboratories dominates the competitive landscape with 22% market share, followed by Mylan and other key manufacturers investing in API production and formulation development to meet growing demand.

---

10️⃣ 1. Morepen Laboratories

Headquarters: Bangalore, India
Key Offering: Montelukast Sodium API and finished dosage forms

Morepen Laboratories leads the global market with a robust manufacturing footprint across India and the United States. Their vertically integrated operations enable cost‑efficient production and rapid scale‑up to meet rising demand in North America and Asia‑Pacific.

Sustainability Initiatives:

• Adoption of green chemistry processes reducing solvent usage
• Investment in renewable energy for manufacturing facilities
• Strategic partnerships with regional distributors to expand access in emerging markets

---

9️⃣ 2. Mylan (Viatris)

Headquarters: New York, USA
Key Offering: Montelukast Sodium generic tablets and chewable formulations

Mylan, now part of Viatris, has a strong distribution network and regulatory approvals across multiple therapeutic markets. Their focus on cost‑effective generics has captured significant market share in North America and Europe.

Sustainability Initiatives:

• Implementation of ISO 14001 environmental management systems
• Reduction of carbon footprint through optimized logistics
• Continuous improvement of API synthesis to enhance yield and reduce waste

---

8️⃣ 3. TAPI (Teva Active Pharmaceutical Ingredients)

Headquarters: Ramat Gan, Israel
Key Offering: High‑purity Montelukast Sodium API

TAPI supplies raw material to global manufacturers, leveraging advanced synthesis technologies to deliver high‑quality API at competitive prices.

Sustainability Initiatives:

• Use of recycled solvents in API production
• Investment in water‑recycling systems
• Collaboration with customers on green formulation development

---

7️⃣ 4. MSN Laboratories

Headquarters: Mumbai, India
Key Offering: Montelukast Sodium API and finished dosage forms

MSN Laboratories has expanded capacity to meet growing demand, focusing on cost‑competitive pricing and rapid product launch timelines.

Sustainability Initiatives:

• Implementation of energy‑efficient manufacturing processes
• Waste minimization through process optimization
• Engagement with local communities on health education

---

6️⃣ 5. Ultratech India

Headquarters: Hyderabad, India
Key Offering: Montelukast Sodium API and finished dosage forms

Ultratech India emphasizes rapid scale‑up and robust quality control, supporting both domestic and export markets.

Sustainability Initiatives:

• Adoption of clean energy solutions for manufacturing
• Reduction of greenhouse gas emissions through process efficiencies
• Supplier audit programs to ensure ethical sourcing

---

5️⃣ 6. Aurobindo Pharma

Headquarters: Bangalore, India
Key Offering: Montelukast Sodium tablets and chewable formulations

Aurobindo Pharma leverages its extensive distribution network to deliver cost‑effective generics across emerging markets.

Sustainability Initiatives:

• Implementation of ISO 14001 environmental management
• Water‑conservation initiatives in production facilities
• Community health outreach programs

---

4️⃣ 7. Hetero Labs

Headquarters: Mumbai, India
Key Offering: Montelukast Sodium API and finished dosage forms

Hetero Labs focuses on cost‑efficient production and rapid product launches, catering to both domestic and export markets.

Sustainability Initiatives:

• Energy‑efficient manufacturing processes
• Waste minimization and recycling programs
• Supplier engagement for sustainable sourcing

---

3️⃣ 8. Unimark Remedies

Headquarters: Mumbai, India
Key Offering: Montelukast Sodium generic tablets

Unimark Remedies delivers high‑quality generics with a focus on affordability and accessibility in emerging markets.

Sustainability Initiatives:

• Implementation of green manufacturing practices
• Water‑conservation initiatives
• Community health education programs

---

2️⃣ 9. Jubilant Cadista

Headquarters: Mumbai, India
Key Offering: Montelukast Sodium finished dosage forms

Jubilant Cadista supports a broad portfolio of respiratory therapeutics, emphasizing quality and regulatory compliance.

Sustainability Initiatives:

• ISO 14001 environmental management
• Energy efficiency in manufacturing
• Stakeholder engagement for sustainable development

---

1️⃣ 10. Hengyuan Pharmaceutical

Headquarters: Shanghai, China
Key Offering: Montelukast Sodium API and finished dosage forms

Hengyuan Pharmaceutical has scaled production through technological upgrades, offering competitive pricing in price‑sensitive markets.

Sustainability Initiatives:

• Adoption of green chemistry for API synthesis
• Reduction of energy consumption in manufacturing
• Partnerships with local distributors for market expansion

---

Montelukast Sodium Market – View in Detailed Research Report

Montelukast Sodium Market – View in Detailed Research Report

Outlook

North America remains the leading revenue contributor, driven by high prevalence of asthma and robust healthcare infrastructure. Asia‑Pacific is the fastest‑growing region, projected to expand at a CAGR of 17.3% through 2032, fueled by expanding healthcare access, rising pollution‑related respiratory conditions, and government initiatives to improve asthma management.

Future Trends

• Digital health integration: smart blister packs and telehealth platforms enhance medication adherence and patient monitoring.
• Therapeutic innovation: exploration of montelukast’s anti‑inflammatory potential in COVID‑19 sequelae, neurodegenerative diseases, and certain cancers.
• Pediatric formulation expansion: chewable tablets and oral solutions drive higher compliance among children.
• Price‑competitive generics: continued market penetration reduces treatment costs by 70‑80% relative to branded formulations.
• Supply chain resilience: diversification of API sourcing and investment in cold‑chain infrastructure mitigate distribution bottlenecks.